Since IDH mutants block cell differentiation and promote tumor transformation, and inhibition of mutant IDH (IDHi) can reverse this effect, R-2HG (as the major metabolic product of IDH mutants) has been regarded as an oncometabolite (Rohle et al., 2013; Wang et al., 2013). The gene discussed is IDH2; the disease is neoplasm.